Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of an Intravitreal Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular Age-related Macular Degeneration

NCT03249740 is registered in ClinicalTrials.gov with Graybug Vision as lead sponsor.

NCT NCT03249740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03249740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of an Intravitreal Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular Age-related Macular Degeneration
Lead sponsor
Graybug Vision
Phase
Phase 1
Overall status
Completed
Start date
August 29, 2017
Completion date
January 16, 2019
Enrollment
32 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration